EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect

Nuerbiye Abudurexiti iD, Yidan Lou, Mengqi Wu, Yingchen Huang, Shan Huang, Kaibo Guo, Song Zheng

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70931 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Nuerbiye Abudurexiti und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial 151 Talent Training, Zhejiang Provincial Health High-level Innovative Talent Training, Hangzhou 131 Talent Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib is a small molecule that inhibits receptor tyrosine kinases KIT and platelet‐derived growth factor receptor α (PDGFRA). It was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of advanced, unresectable gastrointestinal stromal tumours (GISTs). Since then, additional kinase inhibitors targeting multiple pathways have also been introduced. However, as treatment with imatinib is prolonged, its effectiveness gradually declines, with 50% of patients experiencing relapse within 2–5 years. This decline in effectiveness is largely attributed to the development of both initial and acquired resistance. Due to these mechanisms of resistance, many advanced GIST patients struggle to achieve long‐term benefits from systemic treatment. This review aims to summarise the mechanisms of resistance to imatinib and their relationship with GIST molecular subtypes, while also exploring the latest strategies to overcome resistance. We discuss the alterations in signalling pathways following imatinib resistance, the disruption of autophagy and glycolysis, the role of microRNAs and immunotherapy in resistant GISTs, and combination therapies. Furthermore, we examine ongoing clinical trials and potential future therapies that could be integrated into clinical practice, offering guidance for new treatment strategies that aim to enhance the prognosis of advanced GIST patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsImatinib MesylateDrug Resistance, NeoplasmProtein Kinase InhibitorsAntineoplastic AgentsGastrointestinal NeoplasmsHumansSignal TransductionAnimalsMicroRNAs

Stichwörter der Autor:innen

drug resistancegastrointestinal stromal tumoursimatinibtarget therapytyrosine kinase inhibitor

Substanzen

Imatinib MesylateProtein Kinase InhibitorsAntineoplastic AgentsMicroRNAs

Autor:innen und Institutionen

  • The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of Oncology, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, China.
  • Key Laboratory of Clinical Cancer Pharmacology & Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, China.
  • Zhejiang University School of Medicine, Hangzhou, China.
  • Hangzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

ORCID-Profile: Nuerbiye Abudurexiti

Förderung

  • Zhejiang Provincial 151 Talent Training
  • Zhejiang Provincial Health High-level Innovative Talent Training
  • Hangzhou 131 Talent Funds
  • Hangzhou 'West Lake Pearl Project' Special Support Talent Funds

Zitieren

APA

Abudurexiti, N., Lou, Y., Wu, M., Huang, Y., Huang, S., Guo, K., & Zheng, S. (2025). The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70931

Vancouver

Abudurexiti N, Lou Y, Wu M, Huang Y, Huang S, Guo K, et al. The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70931

BibTeX
@article{Abudurexiti2025,
  author = {Abudurexiti, Nuerbiye and Lou, Yidan and Wu, Mengqi and Huang, Yingchen and Huang, Shan and Guo, Kaibo and Zheng, Song},
  title = {The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70931}
}
Kostenlos starten →